BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Coelho LGV, Marinho JR, Genta R, Ribeiro LT, Passos MDCF, Zaterka S, Assumpção PP, Barbosa AJA, Barbuti R, Braga LL, Breyer H, Carvalhaes A, Chinzon D, Cury M, Domingues G, Jorge JL, Maguilnik I, Marinho FP, Moraes-filho JPD, Parente JML, Paula-e-silva CMD, Pedrazzoli-júnior J, Ramos AFP, Seidler H, Spinelli JN, Zir JV. IVTH BRAZILIAN CONSENSUS CONFERENCE ON HELICOBACTER PYLORI INFECTION. Arq Gastroenterol 2018;55:97-121. [DOI: 10.1590/s0004-2803.201800000-20] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Collin A, Mion F, Kefleyesus A, Beets C, Jaafari N, Boussageon R. Critical appraisal of international guidelines for the management of Helicobacter pylori infection in case of dyspepsia. Helicobacter 2023;28:e12952. [PMID: 36897573 DOI: 10.1111/hel.12952] [Reference Citation Analysis]
2 Katelaris P, Hunt R, Bazzoli F, Cohen H, Fock KM, Gemilyan M, Malfertheiner P, Mégraud F, Piscoya A, Quach D, Vakil N, Vaz Coelho LG, LeMair A, Melberg J. Helicobacter pylori World Gastroenterology Organization Global Guideline. J Clin Gastroenterol 2023;57:111-26. [PMID: 36598803 DOI: 10.1097/MCG.0000000000001719] [Reference Citation Analysis]
3 Ji YH, Shi YM, Hei QW, Sun JM, Yang XF, Wu T, Sun DL, Qi YX. Evaluation of guidelines for diagnosis and treatment of Helicobacter pylori infection. Helicobacter 2023;28:e12937. [PMID: 36408808 DOI: 10.1111/hel.12937] [Reference Citation Analysis]
4 de Moraes Andrade PV, Monteiro YM, Chehter EZ. Third-line and rescue therapy for refractory Helicobacter pylori infection: A systematic review. World J Gastroenterol 2023; 29(2): 390-409 [PMID: 36687120 DOI: 10.3748/wjg.v29.i2.390] [Reference Citation Analysis]
5 de Paula MN, Ribeiro TDVR, Isolani R, de Medeiros Araújo DC, Borges AS, Philippsen GS, de Cássia Ribeiro Gonçalves R, Kitagawa RR, Seixas FAV, de Mello JCP. An In Vitro and In Silico Investigation about Monteverdia ilicifolia Activity against Helicobacter pylori. Antibiotics (Basel) 2022;12. [PMID: 36671247 DOI: 10.3390/antibiotics12010046] [Reference Citation Analysis]
6 Gonçalves WGE, Santos MHPD, Brito LM, Palheta HGA, Lobato FMF, Demachki S, Ribeiro-Dos-Santos Â, Araújo GS. DeepHP: A New Gastric Mucosa Histopathology Dataset for Helicobacter pylori Infection Diagnosis. Int J Mol Sci 2022;23. [PMID: 36498907 DOI: 10.3390/ijms232314581] [Reference Citation Analysis]
7 Bolat A, Yaprak D, Arslan M, Büyükcam A, Balamtekin N. Assessment of Efficacy and Adverse Effects of Bismuth-Based Treatment Combined with Bifidobacterium Lactis for Eradication of Helicobacter Pylori in Turkish Children. J Pediatr Infect Dis 2022;17:297-302. [DOI: 10.1055/s-0042-1758142] [Reference Citation Analysis]
8 Neves NCV, de Mello MP, Smith SM, Boylan F, Caliari MV, Castilho RO. Chemical Composition and In Vitro Anti-Helicobacter pylori Activity of Campomanesia lineatifolia Ruiz & Pavón (Myrtaceae) Essential Oil. Plants 2022;11:1945. [DOI: 10.3390/plants11151945] [Reference Citation Analysis]
9 Robles C, Rudzite D, Polaka I, Sjomina O, Tzivian L, Kikuste I, Tolmanis I, Vanags A, Isajevs S, Liepniece-Karele I, Razuka-Ebela D, Parshutin S, Murillo R, Herrero R, Young Park J, Leja M. Assessment of Serum Pepsinogens with and without Co-Testing with Gastrin-17 in Gastric Cancer Risk Assessment-Results from the GISTAR Pilot Study. Diagnostics (Basel) 2022;12. [PMID: 35885649 DOI: 10.3390/diagnostics12071746] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Valadares EC, Gestic MA, Utrini MP, Chaim FDM, Chaim EA, Cazzo E. PRE-OPERATIVE SCREENING OF HELICOBACTER PYLORI IN BARIATRIC PATIENTS: IS HISTOPATHOLOGICAL ANALYSIS NECESSARY? Arq Gastroenterol 2022;59:275-280. [DOI: 10.1590/s0004-2803.202202000-49] [Reference Citation Analysis]
11 Brasil-costa I, Souza CDO, Monteiro LCR, Santos MES, Oliveira EHCD, Burbano RMR. H. pylori Infection and Virulence Factors cagA and vacA (s and m Regions) in Gastric Adenocarcinoma from Pará State, Brazil. Pathogens 2022;11:414. [DOI: 10.3390/pathogens11040414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Araújo GRL, Marques HS, Santos MLC, da Silva FAF, da Brito BB, Correa Santos GL, de Melo FF. Helicobacter pylori infection: How does age influence the inflammatory pattern? World J Gastroenterol 2022; 28(4): 402-411 [DOI: 10.3748/wjg.v28.i4.402] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
13 Bai X, Zhu M, He Y, Wang T, Tian D, Shu J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch Microbiol 2022;204:692. [PMID: 36344628 DOI: 10.1007/s00203-022-03314-w] [Reference Citation Analysis]
14 Oliveira AKS, Silva LLL, Miguel MP, Blanco AJV, Carneiro LC, Barbosa MS. HELICOBACTER PYLORI cagA VIRULENCE GENE AND SEVERE ESOGASTRODUODENAL DISEASES: IS THERE AN ASSOCIATION? Arq Gastroenterol 2021;58:468-75. [PMID: 34909852 DOI: 10.1590/S0004-2803.202100000-85] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Fiuza F, Maluf-Filho F, Ide E, Furuya Jr CK, Fylyk SN, Ruas JN, Stabach L, Araujo GA, Matuguma SE, Uemura RS, Sakai CM, Yamazaki K, Ueda SS, Sakai P, Martins BC. Association between mucosal surface pattern under near focus technology and Helicobacter pylori infection. World J Gastrointest Endosc 2021; 13(10): 518-528 [PMID: 34733412 DOI: 10.4253/wjge.v13.i10.518] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Bertges LC, Ferreira AP, Bertges KR, Bertges ER, Costa Carneiro IC, Ignacchiti Lopes Gomes MG. EFFICACY OF PROBIOTICS IN HELICOBACTER PYLORI ERADICATION THERAPY: A SYSTEMATIC REVIEW. GLOBAL JOURNAL FOR RESEARCH ANALYSIS 2021. [DOI: 10.36106/gjra/2310664] [Reference Citation Analysis]
17 de Lima Silva LL, Oliveira AKS, Gama AR, Ramos AFPL, Silva AMTC, Blanco AJV, Vieira JDG, Rasmussem LT, Carneiro LC, Barbosa MS. Helicobacter pylori virulence dupA gene: risk factor or protective factor? Braz J Microbiol 2021. [PMID: 34255308 DOI: 10.1007/s42770-021-00553-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Coelho MCF, Ribeiro HG, Gomes CGO, Marinho FP, Barbosa AJA, Coelho LGV. HELICOBACTER PYLORI CHRONIC GASTRITIS ON PATIENTS WITH PREMALIGNANT CONDITIONS: OLGA AND OLGIM EVALUATION AND SERUM BIOMARKERS PERFORMANCE. Arq Gastroenterol 2021;58:39-47. [PMID: 33909795 DOI: 10.1590/S0004-2803.202100000-08] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Coelho LGV, Coelho MCF. Helicobacter pylori and colorectal neoplasms: a concise review. Arq Gastroenterol 2021;58:114-9. [PMID: 33909789 DOI: 10.1590/S0004-2803.202100000-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Serra MAAO, Medeiros AT, Torres MD, Dias ICCM, Santos CAAS, Araújo MFM. Correlation between the symptoms of upper gastrointestinal disease and endoscopy findings: Implications for clinical practice. J Taibah Univ Med Sci 2021;16:395-401. [PMID: 34140867 DOI: 10.1016/j.jtumed.2020.12.020] [Reference Citation Analysis]
21 Barbuti RC, Schiavon LL, Oliveira CP, Alvares-DA-Silva MR, Sassaki LY, Passos MDCF, Farias AQ, Barros LL, Barreto BP, Albuquerque GBML, Alves AM, Navarro-Rodriguez T, Bittencourt PL. GUT MICROBIOTA, PREBIOTICS, PROBIOTICS, AND SYNBIOTICS IN GASTROINTESTINAL AND LIVER DISEASES: PROCEEDINGS OF A JOINT MEETING OF THE BRAZILIAN SOCIETY OF HEPATOLOGY (SBH), BRAZILIAN NUCLEUS FOR THE STUDY OF HELICOBACTER PYLORI AND MICROBIOTA (NBEHPM), AND BRAZILIAN FEDERATION OF GASTROENTEROLOGY (FBG). Arq Gastroenterol 2020;57:381-98. [PMID: 33331485 DOI: 10.1590/S0004-2803.202000000-72] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Maluf S, Salgado JV, Cysne DN, Camelo DMF, Nascimento JR, Maluf BVT, Silva LDM, Belfort MRC, Silva LA, Guerra RNM, Salgado Filho N, Nascimento FRF. Increased Glycated Hemoglobin Levels in Patients With Helicobacter pylori Infection Are Associated With the Grading of Chronic Gastritis. Front Immunol 2020;11:2121. [PMID: 33013895 DOI: 10.3389/fimmu.2020.02121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 de Oliveira FAB, Mazo DF. Direct access endoscopy in a Brazilian public healthcare facility: comparable results with specialist referred endoscopy. Scand J Gastroenterol 2020;55:970-5. [PMID: 32619367 DOI: 10.1080/00365521.2020.1787500] [Reference Citation Analysis]
24 Santos MLC, de Brito BB, da Silva FAF, Sampaio MM, Marques HS, Oliveira e Silva N, de Magalhães Queiroz DM, de Melo FF. Helicobacter pylori infection: Beyond gastric manifestations. World J Gastroenterol 2020; 26(28): 4076-4093 [PMID: 32821071 DOI: 10.3748/wjg.v26.i28.4076] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
25 Leja M, Chapelle N, Kikuste I, Fedorov E, Sivins A, Carneiro F, Matysiak-budnik T. Gastric Cancer; Prevention and Treatment. Encyclopedia of Gastroenterology 2020. [DOI: 10.1016/b978-0-12-801238-3.11317-0] [Reference Citation Analysis]
26 Leja M, Dumpis U. What Would the Screen-and-Treat Strategy for Helicobacter pylori Mean in Terms of Antibiotic Consumption? Dig Dis Sci 2020;65:1632-42. [PMID: 31659615 DOI: 10.1007/s10620-019-05893-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Krzyżek P, Franiczek R, Krzyżanowska B, Łaczmański Ł, Migdał P, Gościniak G. In Vitro Activity of Sertraline, an Antidepressant, Against Antibiotic-Susceptible and Antibiotic-Resistant Helicobacter pylori Strains. Pathogens 2019;8:E228. [PMID: 31717683 DOI: 10.3390/pathogens8040228] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
28 Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter 2019;24:e12651. [PMID: 31414551 DOI: 10.1111/hel.12651] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
29 O'Connor A, Liou JM, Gisbert JP, O'Morain C. Review: Treatment of Helicobacter pylori Infection 2019. Helicobacter 2019;24 Suppl 1:e12640. [PMID: 31486235 DOI: 10.1111/hel.12640] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 5.5] [Reference Citation Analysis]
30 Leja M, Grinberga-Derica I, Bilgilier C, Steininger C. Review: Epidemiology of Helicobacter pylori infection. Helicobacter 2019;24 Suppl 1:e12635. [PMID: 31486242 DOI: 10.1111/hel.12635] [Cited by in Crossref: 48] [Cited by in F6Publishing: 51] [Article Influence: 12.0] [Reference Citation Analysis]
31 Coelho LGV, Trindade OR, Leão LA, Ribeiro HG, Freitas IS, Coelho MCF. PROSPECTIVE STUDY FOR VALIDATION OF A SINGLE PROTOCOL FOR THE 13C-UREA BREATH TEST USING TWO DIFFERENT DEVICES IN THE DIAGNOSIS OF H. PYLORI INFECTION. Arq Gastroenterol 2019;56:197-201. [PMID: 31460586 DOI: 10.1590/S0004-2803.201900000-38] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Coelho LGV. HELICOBACTER PYLORI: CONTINUING CHALLENGES. Arq Gastroenterol 2018;55:95-96. [DOI: 10.1590/s0004-2803.201800000-37] [Reference Citation Analysis]